Traditional Chinese medicine (TCM) plays an important role in the fight against coronavirus diseasef-2019 (COVID-19) epidemic. A total of 241 Chinese patent medicines and 242 prescriptions were recommended by the state and 26 provinces (autonomous regions and municipalities directly under the central government) for the prevention and treatment of COVID-19. A total of 53 varieties of commonly used medicinal materials were selected by analysis

of which 20 were common key varieties in medicinal materials of Chinese patent medicines and prescriptions

including Glycyrrhizae Radix et Rhizoma

Forsythiae Fructus

Pogostemonis Herba

etc. At the same time

some cold-quilt medicines and ethnic medicines also played an important role in the epidemic. By evaluating the supply and regeneration ability of the key varieties of TCM resources under the current COVID-19 epidemic situation

means of the source

regeneration cycle

medicinal parts

new production and market information of 53 kinds of TCM at present

it is suggested that the artificial cultivation of Glycyrrhizae Radix et Rhizoma and Paeoniae Radix Rubra can be strengthened

the development of Lonicerae Japonicae Flos

Isatidis Radix and other domestic medicinal materials can be controlled. In response to the change in market demand

the production variety structure and planting area of Chinese medicinal materials were timely adjusted to improve the quality standard and safety index of Chinese medicinal materials

and in order to provide ideas for the rational allocation of TCM resources and the development of Chinese medicinal materials industry under the epidemic situation.